Jerusalem, 13 January, 2026 (TPS-IL) — Haifa-based biotech company MeMed has been awarded a $2 million grant from Israel’s Innovation Authority to establish the country’s first acute-care diagnostics and proteomics biobank. The initiative will accelerate development of AI-powered diagnostic tools for high-risk patients by combining biospecimens with clinical data and immune profiling.
MeMed’s biobank aims to address critical gaps in emergency medicine, where clinicians face high-stakes decisions without real-time biological insight. The company’s MeMed BV test is already FDA-cleared for distinguishing bacterial from viral infections in 15 minutes, while its MeMed Severity tool has received FDA Breakthrough Device Designation for predicting severe outcomes in acute infections.